These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35229004)

  • 1. Systemic and local immune responses to intraocular AAV vector administration in non-human primates.
    Ail D; Ren D; Brazhnikova E; Nouvel-Jaillard C; Bertin S; Mirashrafi SB; Fisson S; Dalkara D
    Mol Ther Methods Clin Dev; 2022 Mar; 24():306-316. PubMed ID: 35229004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies.
    Haar J; Blazevic D; Strobel B; Kreuz S; Michelfelder S
    Mol Ther Methods Clin Dev; 2022 Jun; 25():360-369. PubMed ID: 35573045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
    Ros-Gañán I; Hommel M; Trigueros-Motos L; Tamarit B; Rodríguez-García E; Salas D; Pérez G; Douar A; Combal JP; Benichou B; Ferrer V; González-Aseguinolaza G
    Clin Transl Immunology; 2022; 11(2):e1375. PubMed ID: 35228870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
    Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
    J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
    Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
    Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.
    Wang L; Calcedo R; Wang H; Bell P; Grant R; Vandenberghe LH; Sanmiguel J; Morizono H; Batshaw ML; Wilson JM
    Mol Ther; 2010 Jan; 18(1):126-34. PubMed ID: 19888196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.
    Day TP; Byrne LC; Flannery JG; Schaffer DV
    Methods Mol Biol; 2018; 1715():239-249. PubMed ID: 29188518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Neutralizing Antibody Production on AAV-PHP.B-Mediated Transduction of the Mouse Central Nervous System.
    Shinohara Y; Konno A; Nitta K; Matsuzaki Y; Yasui H; Suwa J; Hiromura K; Hirai H
    Mol Neurobiol; 2019 Jun; 56(6):4203-4214. PubMed ID: 30291583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Same-Eye Subretinal Sequential Readministration of
    Weed L; Ammar MJ; Zhou S; Wei Z; Serrano LW; Sun J; Lee V; Maguire AM; Bennett J; Aleman TS
    Mol Ther Methods Clin Dev; 2019 Dec; 15():133-148. PubMed ID: 31660416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
    Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
    Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
    Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
    J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates.
    Yiu G; Chung SH; Mollhoff IN; Nguyen UT; Thomasy SM; Yoo J; Taraborelli D; Noronha G
    Mol Ther Methods Clin Dev; 2020 Mar; 16():179-191. PubMed ID: 32055646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.
    Gao GP; Alvira MR; Wang L; Calcedo R; Johnston J; Wilson JM
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11854-9. PubMed ID: 12192090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.
    Tse LV; Klinc KA; Madigan VJ; Castellanos Rivera RM; Wells LF; Havlik LP; Smith JK; Agbandje-McKenna M; Asokan A
    Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4812-E4821. PubMed ID: 28559317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.
    Barker SE; Broderick CA; Robbie SJ; Duran Y; Natkunarajah M; Buch P; Balaggan KS; MacLaren RE; Bainbridge JW; Smith AJ; Ali RR
    J Gene Med; 2009 Jun; 11(6):486-97. PubMed ID: 19340848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.